UNLABELLED: Hepatitis C virus (HCV) infection has been associated with reduced bone mineral density, but its association with fracture rates is unknown, particularly in the setting of human immunodeficiency virus (HIV) coinfection. Our aims were to determine whether persons with HCV infection alone are at increased risk for hip fracture, compared to uninfected individuals, and to examine whether the risk of hip fracture is higher among HCV/HIV-coinfected persons, compared to those with HCV alone, those with HIV alone, and those uninfected with either virus. We conducted a cohort study in 36,950 HCV/HIV-coinfected, 276,901 HCV-monoinfected, 95,827 HIV-monoinfected, and 3,110,904 HCV/HIV-uninfected persons within the U.S. Medicaid populations of California, Florida, New York, Ohio, and Pennsylvania (1999-2005). Incidence rates of hip fracture were lowest among uninfected persons (1.29 events/1,000 person-years), increased with the presence of either HIV infection (1.95 events/1,000 person-years) or HCV infection (2.69 events/1,000 person-years), and were highest among HCV/HIV-coinfected individuals (3.06 events/1,000 person-years). HCV/HIV coinfection was associated with an increased relative hazard (adjusted hazard ratio [HR] [95% confidence interval; CI]) of hip fracture, compared to HCV-monoinfected (HR, 1.38; 95% CI: 1.25-1.53), HIV-monoinfected (females: HR, 1.76; 95% CI: 1.44-2.16; males: HR, 1.36; 95% CI: 1.20-1.55), and HCV/HIV-uninfected persons (females: HR, 2.65; 95% CI: 2.21-3.17; males: HR, 2.20; 95% CI: 1.97-2.47). HCV monoinfection was associated with an increased risk of hip fracture, compared to uninfected individuals, and the relative increase was highest in the youngest age groups (females, 18-39 years: HR, 3.56; 95% CI: 2.93-4.32; males, 18-39 years: HR, 2.40; 95% CI: 2.02-2.84). CONCLUSION: Among Medicaid enrollees, HCV/HIV coinfection was associated with increased rates of hip fracture, compared to HCV-monoinfected, HIV-monoinfected, and HCV/HIV-uninfected persons. HCV-monoinfected patients had an increased risk of hip fracture, compared to uninfected individuals.
UNLABELLED: Hepatitis C virus (HCV) infection has been associated with reduced bone mineral density, but its association with fracture rates is unknown, particularly in the setting of human immunodeficiency virus (HIV) coinfection. Our aims were to determine whether persons with HCV infection alone are at increased risk for hip fracture, compared to uninfected individuals, and to examine whether the risk of hip fracture is higher among HCV/HIV-coinfectedpersons, compared to those with HCV alone, those with HIV alone, and those uninfected with either virus. We conducted a cohort study in 36,950 HCV/HIV-coinfected, 276,901 HCV-monoinfected, 95,827 HIV-monoinfected, and 3,110,904 HCV/HIV-uninfectedpersons within the U.S. Medicaid populations of California, Florida, New York, Ohio, and Pennsylvania (1999-2005). Incidence rates of hip fracture were lowest among uninfected persons (1.29 events/1,000 person-years), increased with the presence of either HIV infection (1.95 events/1,000 person-years) or HCV infection (2.69 events/1,000 person-years), and were highest among HCV/HIV-coinfected individuals (3.06 events/1,000 person-years). HCV/HIV coinfection was associated with an increased relative hazard (adjusted hazard ratio [HR] [95% confidence interval; CI]) of hip fracture, compared to HCV-monoinfected (HR, 1.38; 95% CI: 1.25-1.53), HIV-monoinfected (females: HR, 1.76; 95% CI: 1.44-2.16; males: HR, 1.36; 95% CI: 1.20-1.55), and HCV/HIV-uninfectedpersons (females: HR, 2.65; 95% CI: 2.21-3.17; males: HR, 2.20; 95% CI: 1.97-2.47). HCV monoinfection was associated with an increased risk of hip fracture, compared to uninfected individuals, and the relative increase was highest in the youngest age groups (females, 18-39 years: HR, 3.56; 95% CI: 2.93-4.32; males, 18-39 years: HR, 2.40; 95% CI: 2.02-2.84). CONCLUSION: Among Medicaid enrollees, HCV/HIV coinfection was associated with increased rates of hip fracture, compared to HCV-monoinfected, HIV-monoinfected, and HCV/HIV-uninfectedpersons. HCV-monoinfectedpatients had an increased risk of hip fracture, compared to uninfected individuals.
Authors: Linda Gilbert; Xiaofei He; Paul Farmer; Janet Rubin; Hicham Drissi; Andre J van Wijnen; Jane B Lian; Gary S Stein; Mark S Nanes Journal: J Biol Chem Date: 2001-11-26 Impact factor: 5.157
Authors: S Pignata; B Daniele; M G Galati; G Esposito; P Vallone; F Fiore; P Ricchi; M Pergola Journal: Eur J Gastroenterol Hepatol Date: 1997-03 Impact factor: 2.566
Authors: Kristin Mondy; Kevin Yarasheski; William G Powderly; Michael Whyte; Sherry Claxton; Debra DeMarco; Mary Hoffmann; Pablo Tebas Journal: Clin Infect Dis Date: 2003-01-29 Impact factor: 9.079
Authors: D D Byrne; C W Newcomb; D M Carbonari; M S Nezamzadeh; K B F Leidl; M Herlim; Y X Yang; S Hennessy; J R Kostman; M B Leonard; A R Localio; V Lo Re Journal: J Viral Hepat Date: 2015-03-06 Impact factor: 3.728
Authors: Vincent Lo Re; Kenneth Lynn; Emily R Stumm; Jin Long; Melissa S Nezamzadeh; Joshua F Baker; Andrew N Hoofnagle; Angela J Kapalko; Karam Mounzer; Babette S Zemel; Pablo Tebas; Jay R Kostman; Mary B Leonard Journal: J Infect Dis Date: 2015-03-09 Impact factor: 5.226
Authors: Julie A Womack; Joseph L Goulet; Cynthia Gibert; Cynthia A Brandt; Melissa Skanderson; Barbara Gulanski; David Rimland; Maria C Rodriguez-Barradas; Janet Tate; Michael T Yin; Amy C Justice Journal: Clin Infect Dis Date: 2013-02-01 Impact factor: 9.079
Authors: Vincent Lo Re; Charitha Gowda; Paul N Urick; Joshua T Halladay; Amanda Binkley; Dena M Carbonari; Kathryn Battista; Cassandra Peleckis; Jody Gilmore; Jason A Roy; Jalpa A Doshi; Peter P Reese; K Rajender Reddy; Jay R Kostman Journal: Clin Gastroenterol Hepatol Date: 2016-04-05 Impact factor: 11.382